TANGO THERAPEUTICS INC
TNGXNASDAQTrading Snapshot
- Day Range
- $25.95 – $26.81
- 52-Week Range
- $6.25 – $34.39
- Volume
- $3.92B
- Avg Volume
- $3.94B
- Shares Outstanding
- 162.3M
- Next Earnings
- Oct 29, 2026
Fundamentals Snapshot
- Annual Revenue
- $62M
- Last Q Revenue
- $15M
- P/E Ratio
- —
- P/S Ratio
- 67.7x
- EPS (TTM)
- $-0.83
- Dividend Yield
- —
Why Investors Own TNGX
- ✓High-growth profile — revenue up +46.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 58% gross margin and 7% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About TANGO THERAPEUTICS INC
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Tango Therapeutics Files Prospectus For Up To $400M Common Stock Offering
Up to $400,000,000Common StockWe have previously entered into a Sales Agreement, or the sales agreement, with Leerink Partners LLC, or Leerink Partners, dated November 21, 2025, relating to the sale of shares of our
Tango Therapeutics Q2 EPS $(0.37) Misses $(0.32) Estimate
Tango Therapeutics (NASDAQ:TNGX) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.32) by 15.62 percent. This is a 5.71 percent decrease over losses of $(0.35) per share
Mizuho Maintains Outperform on Tango Therapeutics, Raises Price Target to $40
Mizuho analyst Joseph Catanzaro maintains Tango Therapeutics (NASDAQ:TNGX) with a Outperform and raises the price target from $36 to $40.
This Veracyte Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Wall Street analysts initiated coverage on various top stocks, including VCYT, UMAC, FISN, LTRX, and TNGX with positive ratings and price targets.
JP Morgan Initiates Coverage On Tango Therapeutics with Overweight Rating, Announces Price Target of $46
JP Morgan analyst Brian Cheng initiates coverage on Tango Therapeutics (NASDAQ:TNGX) with a Overweight rating and announces Price Target of $46.